[English]  [Pусский]  [中文]  
 
ctt-journal > Mikhaylova et al. (Abstract)

Mikhaylova et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract58
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment

 

The prognostic value of pretransplantation positron emission tomography in lymphoma patients

Natalia B. Mikhaylova1, Sergey E. Korolev1, Mariya S. Tlostanova2, Alexander A. Pugachev1, Yuliya N. Vinogradova2, Nikolay V. Ilyin2, Boris V. Afanasyev1

1Memorial R.M.Gorbacheva Institute of Children Hematology and Transplantation, St.Petersburg Pavlov State Medical University, St.Petersburg, Russia; 2Russian Research Centre for Radiology and Surgical Technologies, St.-Petersburg, Russia

Correspondence: Natalia B. Mikhaylova, Memorial R.M.Gorbacheva Institute of Children Hematology and Transplantation, St.Petersburg Pavlov State Medical University, 6/8, Tolstoy str., St.Petersburg, 199044, Russia, E-mail: bmt-lymphoma@spam is badspmu.rssi.ru

Abstract

Objectives: We investigated the ability of fluorine 18-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET ) to predict clinical outcomes after high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/SCT) in patients with Hodgkin’s and non-Hodgkin’s aggressive lymphoma.

Methods: Pre-transplant PET and CT was performed in 48 patients (30 patients with Hodgkin’s lymphoma, 18 patients with aggressive non-Hodgkin’s lymphoma). Twenty patients were PET negative before HSCT and 28 patients were PET positive despite salvage second line chemotherapy (DHAP, ICE, or gemcitabine-containing regimen). According to CT data alone, 9 patients were in CR, 21 patients – in PR, 10 patients had stable disease, and 8 patients had progressive disease.

Results: The median follow-up period was 1 year 10 months. The 3-year overall survival (OS) was 100 % for patients with complete response according to CT data, 67% in patients reaching partial response before HSCT, and 39% for patients with stable or progressive disease at the moment of transplantation (p= 0.021; Fig 1a). PET negative patients had an OS=of 87%, whereas PET-positive patients demonstrated 43% OS (p=0.013; Fig 1b).

Figures 1A, 1B.

Conclusion: FDG-PET is a powerful prognostic factor for patients undergoing auto-HSCT. It could be use for selection of patients for auto-HSCT.

Keywords: lymphoma, positron emission tomography, hematopoietic stem cell transplantation

 

<-- Previous abstract        Contents        Next abstract -->

Contribute a comment

Top